Genentech developed a breakthrough therapy for the treatment of patients living with early Alzheimer's disease (AD). This will be the first medicine to treat Alzheimer’s disease at-home administration.
Gantenerumab is the first investigational IgG1 antibody designed with late-stage trials for the treatment of AD. It binds the aggregated forms of amyloid beta and removes brain amyloid plaques, a pathological hallmark of Alzheimer’s disease (AD).
The pivotal GRADUATE trials carried out for gantenerumab will investigate its effects on amyloid load and downstream biomarkers of disease as well as safety and efficiency of gantenerumab early (prodromal-to-mild) AD in patients.
Alzheimer's disease (AD) is a type of brain disorder causing weaking in memory, language and other problems such as thinking skills, changes in mood and behaviour. Alzheimer's the common form of dementia and it is expected to reach disease population of 78 million by 2030 and currently affecting more than 55 million people globally. Moreover, nearly 10 million people are diagnosed with AD every year.
U.S. Food and Drug administrator has granted breakthrough therapy designation for Gantenerumab, investigational antibody for Alzheimer's disease (AD).
